In March 2022, IGH and implementing partners began conducting a nationwide serosurvey to determine the burden of disease for Hepatitis B, Hepatitis C, and COVID-19 in seven oblasts throughout the Republic of Uzbekistan. The sample size of the serosurvey is 15,000 participants. The collected data underscores the importance of treatment and prevention of infectious diseases to the Ministry of Health and other stakeholders. This has been made possible with support from the Services for Sanitary and Epidemiological Well-being (SSEW) and the Institute of Virology (IOV).
CENTERS FOR DISEASE CONTROL AND
Participants from various oblasts were required to register and complete a questionnaire before being tested for Hepatitis and COVID-19. The questionnaire collects medical demographic information.
IGH and CDC Uzbekistan staff members provided sample collection and data entry training to the seven participating obalsts. These trainings prepared staff to assess the capabilities of medical staff to test and compile the testing information. Monitoring and evaluation were integrated into the survey after the initial site visit.
Medical professionals from regional polyclinics performed blood testing on the participants. The samples were then sent for testing at the Institute of Virology.
CDC’s Deputy Chief of the Laboratory Branch at the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Division, Dr. Salem Kamili visited Tashkent to share previous experience in blood collections, external quality assessments and proficiency testing programs. He provided testing demonstrations for the staff members at IOV.